These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10631457)

  • 1. Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial.
    Fields-Jones S; Koletsky A; Wilding G; O'Rourke M; O'Rourke T; Eckardt J; Yates B; McGuirt C; Burris HA
    Ann Oncol; 1999 Nov; 10(11):1307-10. PubMed ID: 10631457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of vinorelbine in patients with androgen-independent prostate cancer.
    Oudard S; Caty A; Humblet Y; Beauduin M; Suc E; Piccart M; Rolland F; Fumoleau P; Bugat R; Houyau P; Monnier A; Sun X; Montcuquet P; Breza J; Novak J; Gil T; Chopin D
    Ann Oncol; 2001 Jun; 12(6):847-52. PubMed ID: 11484963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer.
    Abratt RP; Brune D; Dimopoulos MA; Kliment J; Breza J; Selvaggi FP; Beuzeboc P; Demkow T; Oudard S
    Ann Oncol; 2004 Nov; 15(11):1613-21. PubMed ID: 15520061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer.
    Colleoni M; Graiff C; Vicario G; Nelli P; Sgarbossa G; Pancheri F; Manente P
    Am J Clin Oncol; 1997 Aug; 20(4):383-6. PubMed ID: 9256895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancer.
    Koletsky AJ; Guerra ML; Kronish L
    Cancer J; 2003; 9(4):286-92. PubMed ID: 12967139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
    Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
    Di Lorenzo G; Autorino R; Perdonà S; De Laurentiis M; D'Armiento M; Cancello G; Mirone V; Imbimbo C; Longo N; Altieri V; Tortora G; Figg WD; De Placido S
    Eur Urol; 2007 Oct; 52(4):1020-7. PubMed ID: 17360103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma.
    Tester W; Ackler J; Tijani L; Leighton J
    Cancer J; 2006; 12(4):299-304. PubMed ID: 16925974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer.
    Di Lorenzo G; Pizza C; Autorino R; De Laurentiis M; Marano O; D'Alessio A; Cancello G; Altieri V; Tortora G; Perdonà S; Bianco AR; De Placido S
    Eur Urol; 2004 Dec; 46(6):712-6. PubMed ID: 15548437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer.
    Sweeney CJ; Monaco FJ; Jung SH; Wasielewski MJ; Picus J; Ansari RH; Dugan WM; Einhorn LH
    Ann Oncol; 2002 Mar; 13(3):435-40. PubMed ID: 11996476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients.
    Carles J; Domenech M; Gelabert-Mas A; Nogue M; Tabernero JM; Arcusa A; Guasch I; Miguel A; Ballesteros JJ; Fabregat X
    Acta Oncol; 1998; 37(2):187-91. PubMed ID: 9636014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study.
    Smith MR; Kaufman D; Oh W; Guerin K; Seiden M; Makatsoris T; Manola J; Kantoff PW
    Cancer; 2000 Oct; 89(8):1824-8. PubMed ID: 11042579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of vinorelbine with low dose prednisone in the treatment of hormone-refractory metastatic prostate cancer.
    Robles C; Furst AJ; Sriratana P; Lai S; Chua L; Donnelly E; Solomon J; Sundaram M; Feun L; Savaraj N
    Oncol Rep; 2003; 10(4):885-9. PubMed ID: 12792740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vinorelbine and prednisone in older cancer patients with hormone-refractory metastatic prostate cancer. A phase II study.
    Tralongo P; Bollina R; Aiello R; Di Mari A; Moruzzi G; Beretta G; Mauceri G; Conti G
    Tumori; 2003; 89(1):26-30. PubMed ID: 12729357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
    Borden LS; Clark PE; Lovato J; Hall MC; Stindt D; Harmon M; M Mohler R; Torti FM
    Cancer; 2006 Sep; 107(5):1093-100. PubMed ID: 16888761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study.
    Morant R; Hsu Schmitz SF; Bernhard J; Thürlimann B; Borner M; Wernli M; Egli F; Forrer P; Streit A; Jacky E; Hanselmann S; Bauer J; Hering F; Schmid HP
    Eur J Cancer; 2002 Aug; 38(12):1626-32. PubMed ID: 12142053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer.
    Carles Galcerán J; Bastus Piulats R; Martín-Broto J; Maroto Rey P; Nogué Aligué M; Domenech Santasusana M; Arcusa Lanza A; Bellmunt Molins J; Colin C; Girard A
    Clin Transl Oncol; 2005 Mar; 7(2):66-73. PubMed ID: 15899211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer.
    Goodin S; Rao KV; Kane M; Dave N; Capanna T; Doyle-Lindrud S; Engle E; Jin L; Todd M; DiPaola RS
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):199-204. PubMed ID: 15838657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral vinorelbine as first line chemotherapy in unfit elderly patients with hormone-refractory prostate cancer.
    Caristi N; Maisano R; Iorfida M; Scimone A; Lupo G; Buda C; Scisca C; Adamo V
    J Chemother; 2008 Jun; 20(3):368-73. PubMed ID: 18606594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: double tubulin targeting.
    Sewak S; Kosmider S; Ganju V; Woollett A; Yeow EG; Le B; Henry M; Debrincat MA; Bell R
    Intern Med J; 2010 Mar; 40(3):201-8. PubMed ID: 19460063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.